![]() ![]() ![]() Lawrence Erlbaum Associates, Hillside, NJ, 1988. The once and future issues of validity: assessing the meaning and consequences of measurement. Coefficient alpha and the internal structure of tests. Disease-specific versus generic measurement of health-related quality of life in insulin-dependent diabetic patients. Parkerson GR Jr, Connis RT, Broadhead WE, Patrick DL, Taylor TR, Tse CK. Generic and disease-specific measures in assessing health care status and quality of life. Quality of life assessment: patient compliance with questionnaire completion. Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Health status: patient and physician judgements. Comparison of perspectives on prostate cancer analyses of survey data. Eur Urol 1997 32 (Suppl 3): 86 - 88.Ĭrawford ED, Bennett CL, Stone NN, Knight SJ, DeAntoni E, Sharp L, et al. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Cancer 1993 72 (12 Suppl): 3803 - 3806.īennett CL, Chapman G, Elstein AS, Knight SJ, Nadler RB, Sharifi R, et al. Quality of life in prostatic cancer patients. Differences in urologist and patients assessments of health related quality of life in men with prostate cancer: results from the Capsure Database. Litwin MS, Lubeck DP, Henning JM, Carroll PR. ![]() Measuring health related quality of life in men with prostate cancer. Measuring and analyzing quality of life in cancer clinical trials: a review. How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. JAMA 1994 272 (8): 619 - 626.Īltwein J, Ekman P, Barry M, Biermann C, Carlsson P, Fossa S, et al. A critical appraisal of the quality-of-life measurements. Measuring the effect of cancer on quality of life. Kluwer Academic Publishers, Dordrecht, 1993, pp. Quality of Life Assessment: Key Issues in the 1990s. Assessing health-related quality of life for clinical decision-making. Assessment of endpoints for clinical trials for localized prostate cancer. Schellhammer P, Cockett A, Boccon-Gibod L, Gospodarowicz M, Krongrad A, Thompson IM, et al. Radiation therapy versus radical prostatectomy in the PSA era: a urologist s view. This process is experimental and the keywords may be updated as the learning algorithm improves. These keywords were added by machine and not by the authors. Given the problems with alternative outcomes and the absence of randomized clinical trial data that clearly identify one treatment modality as superior, the American Urological Association’s practice guidelines committee has stressed the importance of measuring quality of life as an outcome in the study of prostate cancer (2). ![]() In addition, the ultimate clinical significance of a biochemical recurrence remains unclear. PSA-free survival, however, has proven to be problematic, since the definition of a PSA failure depends on the type of treatment received. Because retrospective studies using these outcomes in localized disease have shown that treatments are similar at 5 yr (1), researchers have attempted to use alternative outcomes, such as prostate-specific antigen (PSA) free survival, to identify a superior treatment modality. Traditionally, overall and disease-specific mortality rates have been used to compare the effect of surgery to radiotherapy in the treatment of localized disease. One of the most challenging problems in prostate cancer research is identifying meaningful end points for use in studies assessing treatment efficacy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |